These same toxicities, severe and lethal cases of ILD and pneumonitis, also occurred in patients treated with additional anti-HER2 ADCs, including trastuzumab duocarmazine and trastuzumab emtansine [66,67]. This evidence concerns the gene ERBB2 and pneumonitis.